Health Care Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents
CONCLUSION: Treatment of HER2-positive mBC is a substantial economic burden. A potential approach to minimizing cost and HCRU is to prevent recurrence.PMID:35067467 | DOI:10.1016/j.clbc.2021.11.013 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 24, 2022 Category: Cancer & Oncology Authors: Reshma Mahtani Nina Oestreicher Deepa Lalla Augustina Ogbonnaya Vishal Saundankar Joanne Willey Anna D Coutinho Kelly McCann Source Type: research

Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapy
In conclusion, PET/MRI is a different diagnostic approach that utilizes a multi-modality system. It demonstrates reasonable diagnostic accuracies of the responses of NAC with reference to hormonal subtypes in breast cancer.PMID:35070299 | PMC:PMC8764658 | DOI:10.3892/mco.2021.2483 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 24, 2022 Category: Cancer & Oncology Authors: Chikako Sekine Nachiko Uchiyama Chikashi Watase Takeshi Murata Sho Shiino Kenjiro Jimbo Eriko Iwamoto Shin Takayama Hiroaki Kurihara Kaishi Satomi Masayuki Yoshida Takayuki Kinoshita Akihiko Suto Source Type: research

HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
CONCLUSION: Biomarker status should be reassessed after NACT especially in luminal subtypes.PMID:35071526 | PMC:PMC8727267 | DOI:10.12998/wjcc.v10.i1.260 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 24, 2022 Category: Cancer & Oncology Authors: Luo Wang Qi Jiang Meng-Ye He Peng Shen Source Type: research

Diagnosis and guidance of treatment of breast cancer cutaneous metastases by multiple needle biopsy: A case report
CONCLUSION: Repeated puncture should be performed for advanced breast cancer with skin metastasis, in order to obtain the pathology and directly determine diagnosis when the disease progresses. The treatment should focus on controlling the systemic metastasis, rather than the local disease.PMID:35071538 | PMC:PMC8727255 | DOI:10.12998/wjcc.v10.i1.345 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 24, 2022 Category: Cancer & Oncology Authors: Zhong-Hui Li Fang Wang Ping Zhang Peng Xue Shi-Jie Zhu Source Type: research

Ductal breast carcinoma metastasized to the rectum: A case report and review of the literature
CONCLUSION: Rectal metastasis should be considered when patients with a history of BC present with changed bowel habits.PMID:35071565 | PMC:PMC8717501 | DOI:10.12998/wjcc.v9.i36.11346 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 24, 2022 Category: Cancer & Oncology Authors: Bo Ban Kai Zhang Jian-Nan Li Tong-Jun Liu Jian Shi Source Type: research

Impact of Cold Therapy on Paclitaxel-Induced Peripheral Neuropathy and Quality of Life in Patients With Breast Cancer
Clin J Oncol Nurs. 2022 Feb 1;26(1):93-99. doi: 10.1188/22.CJON.93-99.ABSTRACTBACKGROUND: Taxane drugs frequently produce peripheral neuropathy (PN). Cold therapy to hands and feet during chemotherapy has been effective in reducing PN.OBJECTIVES: The purpose was to compare the frequency and severity of PN and quality of life in patients with breast cancer receiving cold therapy to their hands and feet versus standard of care during 12 weekly paclitaxel infusions with a follow-up at 16 weeks.METHODS: Forty-eight female participants were consecutively recruited and randomized to treatment versus control groups. This randomiz...
Source: Clinical Genitourinary Cancer - January 24, 2022 Category: Cancer & Oncology Authors: Mei-Ying Jue Dipti Shah Anne Stiles Tariq Nisar Source Type: research

Patients With Breast Cancer Receiving Chemotherapy: Effects of Multisensory Stimulation Training on Cognitive Impairment
This study observed the interventional effects of multisensory stimulation training on CRCI in patients with breast cancer receiving chemotherapy.METHODS: Eighty patients with breast cancer receiving chemotherapy at a grade A tertiary hospital in Tangshan City, Hebei Province, China, were divided into two intervention groups (audiovisual and multisensory) by random sampling (40 patients per group).FINDINGS: After four intervention cycles, participants' cognitive and executive function scores were higher in the multisensory group than in the audiovisual group. Multisensory stimulation training had stronger effects than audi...
Source: Clinical Genitourinary Cancer - January 24, 2022 Category: Cancer & Oncology Authors: Zeyuan Li Xijun Hao Ping Lei Lizhi Zhou Changxiang Chen Tingting Tan Liming Yue Source Type: research

Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors
Clin Transl Oncol. 2022 Jan 23. doi: 10.1007/s12094-022-02779-x. Online ahead of print.ABSTRACTSolid tumors including skin, lung, breast, colon, and prostate cancers comprise the most diagnosed cancers worldwide. Treatment of such cancers is still challenging specially in the advanced/metastatic setting. The growing understanding of the tumor microenvironment has revolutionized the cancer therapy paradigms. Targeting programmed death-1 (PD-1)/PD-L1 immune checkpoint has been extensively studied over this decade as a new trend in the management of hard-to-treat cancers by harnessing the power of the immune system to eradica...
Source: Clinical Genitourinary Cancer - January 23, 2022 Category: Cancer & Oncology Authors: Nada K Sedky Alyaa A Hamdan Salma Emad Aya L Allam Mohamed Ali Mai F Tolba Source Type: research

Tau and Stathmin proteins in breast cancer: a potential therapeutic target
Clin Exp Pharmacol Physiol. 2022 Jan 23. doi: 10.1111/1440-1681.13622. Online ahead of print.ABSTRACTBreast cancer is the most common malignant neoplasm among women, responsible for 30% of all malignant tumors, and the second most significant reason of cancer fatality in women. Treatment failure and tumor recurrence are common outcomes of chemotherapy when patients develop multidrug resistance (MDR). New therapeutic methods like molecularly targeted therapeutic interventions need a thorough understanding of malignant tumor's molecular processes. Numerous studies published in the last few years indicate that stathmin and tu...
Source: Clinical Genitourinary Cancer - January 23, 2022 Category: Cancer & Oncology Authors: Hanzhao Yang Source Type: research

Pregnancy after breast cancer in BRCA1/2 mutation carriers
CONCLUSION: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients' needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.PMID:35062994 | DOI:10.1186/s13053-022-00209-1 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Jelena Maksimenko Arv īds Irmejs J ānis Gardovskis Source Type: research

Roles of enhancer RNAs in sex hormone-dependent cancers
CONCLUSION: Abnormal overexpression of eRNAs is mostly oncogenic, leading to cancer progression, and both strands of eRNAs play multiple and complex roles at cis and trans loci in sex hormones mediated pathways, which are tightly associated with sex hormone-dependent tumorigenesis.PMID:35064362 | DOI:10.1007/s00432-021-03886-y (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Lu Zhang Xiaoxia Ye Jieyi Luo Jiayu Chen Weirang Zheng Minhua Wu Source Type: research

An unusual case of gastric outlet obstruction and melena
Clin J Gastroenterol. 2022 Jan 22. doi: 10.1007/s12328-021-01584-3. Online ahead of print.ABSTRACTStrongyloidiasis is a parasitic infection caused by nematode helminth Strongyloides stercoralis. Severe infection with S. stercoralis is rare and often missed by clinicians which may cause worsen the outcomes. A 57-year-old Hispanic female with past medical history of HIV and breast cancer was transferred from an outside hospital to a tertiary care facility with complaint of persistent abdominal pain and melena. She underwent Esophagogastroduodenoscopy (EGD) twice before her presentation for the same complaints which showed se...
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Aysha Aslam Usman Barlas Lindsay J Yassan Maham Lodhi Source Type: research

Perspectives on the role of breast cancer susceptibility gene in breast cancer
Int J Clin Oncol. 2022 Jan 22. doi: 10.1007/s10147-021-02098-1. Online ahead of print.ABSTRACTPURPOSE: Breast cancer susceptibility gene 1/2 can repair damaged DNA through homologous recombination. Besides, the local immune microenvironment of breast cancer is closely linked to the prognosis of patients. But the relationship of breast cancer susceptibility gene 1/2 expression and local immunosuppressive microenvironment in breast cancer is not clear. The aim of this study was to discuss the correlation between them.METHODS: The fresh primary breast tumors and paired normal tissues of 156 cases of breast cancer patients as ...
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Nan Wu Lijuan Wei Lijuan Li Fangxuan Li Jinpu Yu Juntian Liu Source Type: research

Pregnancy after breast cancer in BRCA1/2 mutation carriers
CONCLUSION: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients' needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.PMID:35062994 | DOI:10.1186/s13053-022-00209-1 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Jelena Maksimenko Arv īds Irmejs J ānis Gardovskis Source Type: research

Roles of enhancer RNAs in sex hormone-dependent cancers
CONCLUSION: Abnormal overexpression of eRNAs is mostly oncogenic, leading to cancer progression, and both strands of eRNAs play multiple and complex roles at cis and trans loci in sex hormones mediated pathways, which are tightly associated with sex hormone-dependent tumorigenesis.PMID:35064362 | DOI:10.1007/s00432-021-03886-y (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Lu Zhang Xiaoxia Ye Jieyi Luo Jiayu Chen Weirang Zheng Minhua Wu Source Type: research

An unusual case of gastric outlet obstruction and melena
Clin J Gastroenterol. 2022 Jan 22. doi: 10.1007/s12328-021-01584-3. Online ahead of print.ABSTRACTStrongyloidiasis is a parasitic infection caused by nematode helminth Strongyloides stercoralis. Severe infection with S. stercoralis is rare and often missed by clinicians which may cause worsen the outcomes. A 57-year-old Hispanic female with past medical history of HIV and breast cancer was transferred from an outside hospital to a tertiary care facility with complaint of persistent abdominal pain and melena. She underwent Esophagogastroduodenoscopy (EGD) twice before her presentation for the same complaints which showed se...
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Aysha Aslam Usman Barlas Lindsay J Yassan Maham Lodhi Source Type: research

Perspectives on the role of breast cancer susceptibility gene in breast cancer
Int J Clin Oncol. 2022 Jan 22. doi: 10.1007/s10147-021-02098-1. Online ahead of print.ABSTRACTPURPOSE: Breast cancer susceptibility gene 1/2 can repair damaged DNA through homologous recombination. Besides, the local immune microenvironment of breast cancer is closely linked to the prognosis of patients. But the relationship of breast cancer susceptibility gene 1/2 expression and local immunosuppressive microenvironment in breast cancer is not clear. The aim of this study was to discuss the correlation between them.METHODS: The fresh primary breast tumors and paired normal tissues of 156 cases of breast cancer patients as ...
Source: Clinical Genitourinary Cancer - January 22, 2022 Category: Cancer & Oncology Authors: Nan Wu Lijuan Wei Lijuan Li Fangxuan Li Jinpu Yu Juntian Liu Source Type: research

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women
CONCLUSIONS: PD-L1 serum levels can predict DFS in African American and Hispanic women with breast cancer. Furthermore, a high level of PD-L1 is more likely to be associated with tumor loss PTEN and the activation of Akt or with breast cancer cells expressing CD44high/CD24low. Further validation studies are needed to determine if PD-L1 could serve as a biomarker for patient selection for anti-PD-L1 therapy and assess treatment outcomes.PMID:35053979 | DOI:10.3390/jcm11020283 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Yanyuan Wu Pranabananda Dutta Sheilah Clayton Amaya McCloud Jaydutt V Vadgama Source Type: research

A Systematic Review of Nutritional Lab Correlates with Chemotherapy Induced Peripheral Neuropathy
J Clin Med. 2022 Jan 12;11(2):355. doi: 10.3390/jcm11020355.ABSTRACTChemotherapy induced peripheral neuropathy (CIPN) is a dose-limiting side effect of chemotherapy for which no prevention or cure exists. Cancer and cancer treatments can adversely affect nutritional status. Nutrition may play a role in development of CIPN, yet the relationship between nutrition and CIPN is not well understood. Common laboratory values measuring various aspects of nutrition (hemoglobin/hematocrit, vitamin B12, calcium, and magnesium) may be associated with CIPN. The aim of this systematic review is to evaluate the empirical evidence surroun...
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Cindy Tofthagen Mary Tanay Adam Perlman Jason Starr Pooja Advani Katharine Sheffield Tara Brigham Source Type: research

Prognostic Value of Galectin Expression in Patients with Breast Cancer: Systematic Review and Meta-Analysis
In conclusion, galectin-3 correlates with OS in breast cancer when cellular localization is considered while galectin-7 correlates with DFS/PFS/DSS. The cellular localization of galectins should be as fundamental aspect to be determined in future studies.PMID:35058144 | DOI:10.1016/j.clbc.2021.12.011 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Juan Carlos Ramos-Mart ínez Gerardo Altamirano-G ómez Ivan Ramos-Mart ínez Jorge Valencia Luis Hern ández-Zimbrón Jes ús Hernández-Juárez Patricia Echeverr ía-Vásquez Leticia L Hern ández-González Eduardo P érez-Campos Laura P érez-Campos Ma Source Type: research

Care pathway of women with interval breast cancer in 2016, based on medico-administrative data
CONCLUSION: The care pathways of women with IC are intermediate with respect to those of the OS or PSCS group.Cases of IC probably include several cancer prognosis profiles.PMID:35058145 | DOI:10.1016/j.clbc.2021.12.003 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Christine Le Bihan-Benjamin Camille Bertrand Florence Molini é Agn ès Rogel Jean-Baptiste M éric Norbert Ifrah Philippe-Jean Bousquet Source Type: research

RBE-weighted dose and its impact on the risk of acute coronary event for breast cancer patients treated with intensity modulated proton therapy
CONCLUSION: All three RBE models predicted a higher biological dose compared to the clinical standard dose assuming a constant RBE of 1.1. An underestimation of the biological dose results in underestimation of the ACE risk. Analyzing the voxel-by-voxel biological dose and the LET map alongside clinical outcomes is warranted in the development of a more accurate normal-tissue complication probability model.PMID:35060317 | DOI:10.1002/acm2.13527 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Chunbo Liu Julie A Bradley Dandan Zheng Raymond B Mailhot Vega Chris J Beltran Nancy Mendenhall Xiaoying Liang Source Type: research

Physical Activity Patterns and Cognitive Function in Patients With Breast Cancer
J Clin Oncol. 2022 Jan 21:JCO2102073. doi: 10.1200/JCO.21.02073. Online ahead of print.NO ABSTRACTPMID:35061503 | DOI:10.1200/JCO.21.02073 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Shipeng Ning Kun Qiao Linghui Pan Source Type: research

Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care
CONCLUSION: We propose a predictive model to assess fatigue among breast cancer survivors, within a personalized survivorship care framework. This may help clinicians to provide early management interventions or to correct modifiable risk factors and offer more tailored monitoring and education to patients at risk of severe post-treatment fatigue.PMID:35061509 | DOI:10.1200/JCO.21.01252 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Antonio Di Meglio Julie Havas Davide Soldato Daniele Presti Elise Martin Barbara Pistilli Gwenn Menvielle Agnes Dumas Cecile Charles Sibille Everhard Anne-Laure Martin Charles Coutant Carole Tarpin Laurence Vanlemmens Christelle Levy Olivier Rigal Suzette Source Type: research

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial
CONCLUSION: Patients with an ultralow-risk 70-gene signature have the best prognosis, distinctive from low risk, with 8-year BCSS above 99%, and very few patients developed distant metastases with an 8-year DMFI rate of 97%. These patients could be candidates for further de-escalation of treatment, to avoid overtreatment and the risk of side effects.PMID:35061525 | DOI:10.1200/JCO.21.02019 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Josephine M N Lopes Cardozo Caroline A Drukker Emiel J T Rutgers Marjanka K Schmidt Annuska M Glas Anke Witteveen Fatima Cardoso Martine Piccart Laura J Esserman Coralie Poncet Laura J van 't Veer Source Type: research

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women
CONCLUSIONS: PD-L1 serum levels can predict DFS in African American and Hispanic women with breast cancer. Furthermore, a high level of PD-L1 is more likely to be associated with tumor loss PTEN and the activation of Akt or with breast cancer cells expressing CD44high/CD24low. Further validation studies are needed to determine if PD-L1 could serve as a biomarker for patient selection for anti-PD-L1 therapy and assess treatment outcomes.PMID:35053979 | DOI:10.3390/jcm11020283 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Yanyuan Wu Pranabananda Dutta Sheilah Clayton Amaya McCloud Jaydutt V Vadgama Source Type: research

A Systematic Review of Nutritional Lab Correlates with Chemotherapy Induced Peripheral Neuropathy
J Clin Med. 2022 Jan 12;11(2):355. doi: 10.3390/jcm11020355.ABSTRACTChemotherapy induced peripheral neuropathy (CIPN) is a dose-limiting side effect of chemotherapy for which no prevention or cure exists. Cancer and cancer treatments can adversely affect nutritional status. Nutrition may play a role in development of CIPN, yet the relationship between nutrition and CIPN is not well understood. Common laboratory values measuring various aspects of nutrition (hemoglobin/hematocrit, vitamin B12, calcium, and magnesium) may be associated with CIPN. The aim of this systematic review is to evaluate the empirical evidence surroun...
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Cindy Tofthagen Mary Tanay Adam Perlman Jason Starr Pooja Advani Katharine Sheffield Tara Brigham Source Type: research

Prognostic Value of Galectin Expression in Patients with Breast Cancer: Systematic Review and Meta-Analysis
In conclusion, galectin-3 correlates with OS in breast cancer when cellular localization is considered while galectin-7 correlates with DFS/PFS/DSS. The cellular localization of galectins should be as fundamental aspect to be determined in future studies.PMID:35058144 | DOI:10.1016/j.clbc.2021.12.011 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Juan Carlos Ramos-Mart ínez Gerardo Altamirano-G ómez Ivan Ramos-Mart ínez Jorge Valencia Luis Hern ández-Zimbrón Jes ús Hernández-Juárez Patricia Echeverr ía-Vásquez Leticia L Hern ández-González Eduardo P érez-Campos Laura P érez-Campos Ma Source Type: research

Care pathway of women with interval breast cancer in 2016, based on medico-administrative data
CONCLUSION: The care pathways of women with IC are intermediate with respect to those of the OS or PSCS group.Cases of IC probably include several cancer prognosis profiles.PMID:35058145 | DOI:10.1016/j.clbc.2021.12.003 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Christine Le Bihan-Benjamin Camille Bertrand Florence Molini é Agn ès Rogel Jean-Baptiste M éric Norbert Ifrah Philippe-Jean Bousquet Source Type: research

RBE-weighted dose and its impact on the risk of acute coronary event for breast cancer patients treated with intensity modulated proton therapy
CONCLUSION: All three RBE models predicted a higher biological dose compared to the clinical standard dose assuming a constant RBE of 1.1. An underestimation of the biological dose results in underestimation of the ACE risk. Analyzing the voxel-by-voxel biological dose and the LET map alongside clinical outcomes is warranted in the development of a more accurate normal-tissue complication probability model.PMID:35060317 | DOI:10.1002/acm2.13527 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Chunbo Liu Julie A Bradley Dandan Zheng Raymond B Mailhot Vega Chris J Beltran Nancy Mendenhall Xiaoying Liang Source Type: research

Physical Activity Patterns and Cognitive Function in Patients With Breast Cancer
J Clin Oncol. 2022 Jan 21:JCO2102073. doi: 10.1200/JCO.21.02073. Online ahead of print.NO ABSTRACTPMID:35061503 | DOI:10.1200/JCO.21.02073 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Shipeng Ning Kun Qiao Linghui Pan Source Type: research

Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care
CONCLUSION: We propose a predictive model to assess fatigue among breast cancer survivors, within a personalized survivorship care framework. This may help clinicians to provide early management interventions or to correct modifiable risk factors and offer more tailored monitoring and education to patients at risk of severe post-treatment fatigue.PMID:35061509 | DOI:10.1200/JCO.21.01252 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Antonio Di Meglio Julie Havas Davide Soldato Daniele Presti Elise Martin Barbara Pistilli Gwenn Menvielle Agnes Dumas Cecile Charles Sibille Everhard Anne-Laure Martin Charles Coutant Carole Tarpin Laurence Vanlemmens Christelle Levy Olivier Rigal Suzette Source Type: research

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial
CONCLUSION: Patients with an ultralow-risk 70-gene signature have the best prognosis, distinctive from low risk, with 8-year BCSS above 99%, and very few patients developed distant metastases with an 8-year DMFI rate of 97%. These patients could be candidates for further de-escalation of treatment, to avoid overtreatment and the risk of side effects.PMID:35061525 | DOI:10.1200/JCO.21.02019 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Josephine M N Lopes Cardozo Caroline A Drukker Emiel J T Rutgers Marjanka K Schmidt Annuska M Glas Anke Witteveen Fatima Cardoso Martine Piccart Laura J Esserman Coralie Poncet Laura J van 't Veer Source Type: research

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Clin Cancer Res. 2022 Jan 15;28(2):368-377. doi: 10.1158/1078-0432.CCR-21-2275.ABSTRACTPURPOSE: Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies have been approved for advanced cancers in multiple indications, and numerous trials are under way to test new combinations. However, the mechanisms that account for the superiority of approved ICI combinations relative to their constituent monotherapies remain unknown.EXPERIMENTAL DESIGN: We analyzed 13 phase III clinical trials testing combinations of ICIs with each other or other drugs in patients with advanced melanoma and lung, breast, gastric, k...
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: Adam C Palmer Benjamin Izar Haeun Hwangbo Peter K Sorger Source Type: research

The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
CONCLUSION: Neratinib and fulvestrant is active for ER+/HER2mut MBC. Our data supports further evaluation of dual HER2 blockade for the treatment of HER2mut MBC.PMID:35046057 | DOI:10.1158/1078-0432.CCR-21-3418 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: Cynthia X Ma Jingqin Luo Rachel A Freedman Timothy J Pluard Julie R Nangia Janice Lu Frances Valdez-Albini Melody Cobleigh Jason M Jones Nancy U Lin Eric P Winer Paul Kelly Marcom Jill Anderson Shana Thomas Brittney Haas Leslie Bucheit Richard Bryce Alsha Source Type: research

Cancer in Five Countries of the Eastern Mediterranean Region: Epidemiological Trends and Risk Implications
CONCLUSIONS: The association between the spread of the studied risk factors and the high trends of the corresponding cancer types highlights the importance of targeted preventive measures and serve as a guide for evidence-based prevention strategies.PMID:35046199 | DOI:10.4103/njcp.njcp_611_20 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: S A Shurrab A F Al-Badarneh H I Nassar A H Almshnanah Source Type: research

Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria
CONCLUSION: Triple-negative cancer in this study shares some of the known characteristics but also portrays some divergence from the commonly described features.PMID:35046202 | DOI:10.4103/njcp.njcp_437_20 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: A A Liman B Kabir M Abubakar S Abdullahi S A Ahmed S M Shehu Source Type: research

A uniform and versatile surface-guided radiotherapy procedure and workflow for high-quality breast deep-inspiration breath-hold treatment in a multi-center institution
CONCLUSION: The uniform and versatile breast SGRT DIBH procedure and workflow have been developed to ensure smooth and optimal clinical operations, simplify clinical staff training and clinical troubleshooting, and allow high-quality SGRT delivery in a busy multi-center institution.PMID:35049108 | DOI:10.1002/acm2.13511 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: Guang Li Wei Lu Kyle O'Grady Iris Yan Ellen Yorke Laura I Cervino Arriba Simon Powell Linda Hong Source Type: research

Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study
CONCLUSION: Liver-related mortality was the leading cause of mortality in Asian patients with biopsy-confirmed NAFLD. Although fibrosis stage was independently associated with liver-related events, it was not associated with overall mortality after adjusting for confounders, such as histologic features of steatohepatitis.PMID:35051649 | DOI:10.1016/j.cgh.2022.01.002 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: Hideki Fujii Michihiro Iwaki Hideki Hayashi Hidenori Toyoda Satoshi Oeda Hideyuki Hyogo Miwa Kawanaka Asahiro Morishita Kensuke Munekage Kazuhito Kawata Sakura Yamamura Koji Sawada Tatsuji Maeshiro Hiroshi Tobita Yuichi Yoshida Masafumi Naito Asuka Araki Source Type: research

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Clin Cancer Res. 2022 Jan 15;28(2):368-377. doi: 10.1158/1078-0432.CCR-21-2275.ABSTRACTPURPOSE: Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies have been approved for advanced cancers in multiple indications, and numerous trials are under way to test new combinations. However, the mechanisms that account for the superiority of approved ICI combinations relative to their constituent monotherapies remain unknown.EXPERIMENTAL DESIGN: We analyzed 13 phase III clinical trials testing combinations of ICIs with each other or other drugs in patients with advanced melanoma and lung, breast, gastric, k...
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: Adam C Palmer Benjamin Izar Haeun Hwangbo Peter K Sorger Source Type: research

The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
CONCLUSION: Neratinib and fulvestrant is active for ER+/HER2mut MBC. Our data supports further evaluation of dual HER2 blockade for the treatment of HER2mut MBC.PMID:35046057 | DOI:10.1158/1078-0432.CCR-21-3418 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: Cynthia X Ma Jingqin Luo Rachel A Freedman Timothy J Pluard Julie R Nangia Janice Lu Frances Valdez-Albini Melody Cobleigh Jason M Jones Nancy U Lin Eric P Winer Paul Kelly Marcom Jill Anderson Shana Thomas Brittney Haas Leslie Bucheit Richard Bryce Alsha Source Type: research

Cancer in Five Countries of the Eastern Mediterranean Region: Epidemiological Trends and Risk Implications
CONCLUSIONS: The association between the spread of the studied risk factors and the high trends of the corresponding cancer types highlights the importance of targeted preventive measures and serve as a guide for evidence-based prevention strategies.PMID:35046199 | DOI:10.4103/njcp.njcp_611_20 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: S A Shurrab A F Al-Badarneh H I Nassar A H Almshnanah Source Type: research

Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria
CONCLUSION: Triple-negative cancer in this study shares some of the known characteristics but also portrays some divergence from the commonly described features.PMID:35046202 | DOI:10.4103/njcp.njcp_437_20 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: A A Liman B Kabir M Abubakar S Abdullahi S A Ahmed S M Shehu Source Type: research

A uniform and versatile surface-guided radiotherapy procedure and workflow for high-quality breast deep-inspiration breath-hold treatment in a multi-center institution
CONCLUSION: The uniform and versatile breast SGRT DIBH procedure and workflow have been developed to ensure smooth and optimal clinical operations, simplify clinical staff training and clinical troubleshooting, and allow high-quality SGRT delivery in a busy multi-center institution.PMID:35049108 | DOI:10.1002/acm2.13511 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 20, 2022 Category: Cancer & Oncology Authors: Guang Li Wei Lu Kyle O'Grady Iris Yan Ellen Yorke Laura I Cervino Arriba Simon Powell Linda Hong Source Type: research

COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study
CONCLUSION: Despite being eligible for COVID-19 vaccination since March 2021, a substantial minority of patients with cancer remained unvaccinated as of August 2021. Targeted communication and educational resources addressing vaccine safety in the context of cancer are key to promoting vaccine uptake in this vulnerable population.PMID:35043559 | DOI:10.1111/ajco.13754 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Mike Nguyen Nathan Bain Lisa Grech Tammie Choi Sam Harris Hieu Chau Daniel Freeman Alastair Kwok Janne Williams Amelia McCartney Kate Webber Daphne Day Eva Segelov Source Type: research

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506. Online ahead of print.ABSTRACTPURPOSE: CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in stage II-III triple-negative breast cancer. We now report long-term outcomes (LTOs) and correlative science end points.PATIENTS AND METHODS: The Kaplan-Meier method was used to estimate LTOs in 443 patients who initiated study treatment. Log-rank tests and Cox pro...
Source: Clinical Genitourinary Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Jonathan H Shepherd Karla Ballman Mei-Yin C Polley Jordan D Campbell Cheng Fan Sara Selitsky Aranzazu Fernandez-Martinez Joel S Parker Katherine A Hoadley Zhiyuan Hu Yan Li Matthew G Soloway Patricia A Spears Baljit Singh Sara M Tolaney George Somlo Elisa Source Type: research

Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies
CONCLUSION: In addition to leukemia, RAI treatment for childhood and young-adulthood DTC was associated with increased risks of several solid cancers, particularly more than 20 years after exposure, supporting the need for long-term surveillance of these patients.PMID:35044839 | DOI:10.1200/JCO.21.01841 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Elisa Pasqual Sara Schonfeld Lindsay M Morton Daphn ée Villoing Choonsik Lee Amy Berrington de Gonzalez Cari M Kitahara Source Type: research

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
CONCLUSION: This study revealed profound heterogeneity associated with HR status in the clinical outcomes of HER2-positive breast cancer regarding clinicopathological features, metastatic patterns, and prognosis. Prospective studies to optimize therapeutic strategies for HER2-positive subgroups are warranted.PMID:35041101 | DOI:10.1007/s10147-022-02115-x (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 18, 2022 Category: Cancer & Oncology Authors: Yiqun Han Yun Wu Hangcheng Xu Jiayu Wang Binghe Xu Source Type: research

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
J Clin Oncol. 2022 Jan 18:JCO2102647. doi: 10.1200/JCO.21.02647. Online ahead of print.ABSTRACTPURPOSE: To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline.METHODS: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data.RESULTS: Four articles met eligibility criteria and form the evidentiary basis for revision of the previous recommendations.RECOMMENDATIONS: Adjuvant bisphosphonate therapy should be discussed with all postmenopausal patients (natural or th...
Source: Clinical Genitourinary Cancer - January 18, 2022 Category: Cancer & Oncology Authors: Andrea Eisen Mark R Somerfield Melissa K Accordino Phillip S Blanchette Mark J Clemons Sukhbinder Dhesy-Thind Melissa S Dillmon Stella D'Oronzo Glenn G Fletcher Elizabeth S Frank Sigrun Hallmeyer Issam Makhoul Beverly Moy Alia Thawer Joy Y Wu Catherine H Source Type: research

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
CONCLUSION: This study revealed profound heterogeneity associated with HR status in the clinical outcomes of HER2-positive breast cancer regarding clinicopathological features, metastatic patterns, and prognosis. Prospective studies to optimize therapeutic strategies for HER2-positive subgroups are warranted.PMID:35041101 | DOI:10.1007/s10147-022-02115-x (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 18, 2022 Category: Cancer & Oncology Authors: Yiqun Han Yun Wu Hangcheng Xu Jiayu Wang Binghe Xu Source Type: research